Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis.

Focus (American Psychiatric Publishing) Pub Date : 2023-04-01 Epub Date: 2023-04-14 DOI:10.1176/appi.focus.23021006
Samuel T Wilkinson, Daniel Trujillo Diaz, Zachary W Rupp, Anubhav Kidambi, Karina L Ramirez, José M Flores, Victor J Avila-Quintero, T Greg Rhee, Mark Olfson, Michael H Bloch
{"title":"Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis.","authors":"Samuel T Wilkinson, Daniel Trujillo Diaz, Zachary W Rupp, Anubhav Kidambi, Karina L Ramirez, José M Flores, Victor J Avila-Quintero, T Greg Rhee, Mark Olfson, Michael H Bloch","doi":"10.1176/appi.focus.23021006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Suicide is a public health crisis. We conducted a systematic review and meta-analysis of the effects of psychopharmacologic and somatic therapies on suicide risk.</p><p><strong>Methods: </strong>A systematic search of MEDLINE for studies evaluating the effects of pharmacologic (excluding antidepressants) or somatic interventions on suicide risk was conducted. Studies were included if they used a comparison group, reported on suicide death, assessed a psychopharmacological or somatic intervention, and included adults. Study quality was assessed using the Newcastle-Ottawa scale. Fifty-seven studies were included from 2940 reviewed citations.</p><p><strong>Results: </strong>In bipolar disorder, lithium was associated with a reduction in the odds of suicide compared to active controls (odds ratio [OR] = .58, <i>p</i> = .005; <i>k</i> = 12) and compared to placebo/no lithium (OR = .46, <i>p</i> = .009; <i>k</i> = 9). In mixed diagnostic samples, lithium was associated with a reduction in the odds of suicide compared to placebo/no lithium (OR = .27, <i>p</i> < .001; <i>k</i> = 12), but not compared to active controls (OR = .89, <i>p</i> = .468; <i>k</i> = 7). In psychotic disorders, clozapine was associated with a reduction in the odds of suicide (OR = .46, <i>p</i> = .007; <i>k</i> = 7). Associations between suicide death and electroconvulsive therapy (OR = .77, <i>p</i> = .053; <i>k</i> = 11), non-clozapine antipsychotics in bipolar disorder (OR = .73, <i>p</i> = .090; <i>k</i> = 6) and antipsychotics in psychotic disorders (OR = .39, <i>p</i> = .069; <i>k</i> = 6) were not significant. There was no consistent relationship between antiepileptic mood stabilizers and suicide. There were insufficient studies to meta-analyze associations of suicide risk with vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, or transcranial direct current stimulation.</p><p><strong>Conclusion: </strong>Lithium and clozapine have consistent data supporting protective effects against suicide in certain clinical contexts.Reprinted from <i>Depress Anxiety 2022; 39:100-112,</i> with permission from John Wiley and Sons. Copyright © 2022.</p>","PeriodicalId":73036,"journal":{"name":"Focus (American Psychiatric Publishing)","volume":"21 2","pages":"197-208"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focus (American Psychiatric Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1176/appi.focus.23021006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Suicide is a public health crisis. We conducted a systematic review and meta-analysis of the effects of psychopharmacologic and somatic therapies on suicide risk.

Methods: A systematic search of MEDLINE for studies evaluating the effects of pharmacologic (excluding antidepressants) or somatic interventions on suicide risk was conducted. Studies were included if they used a comparison group, reported on suicide death, assessed a psychopharmacological or somatic intervention, and included adults. Study quality was assessed using the Newcastle-Ottawa scale. Fifty-seven studies were included from 2940 reviewed citations.

Results: In bipolar disorder, lithium was associated with a reduction in the odds of suicide compared to active controls (odds ratio [OR] = .58, p = .005; k = 12) and compared to placebo/no lithium (OR = .46, p = .009; k = 9). In mixed diagnostic samples, lithium was associated with a reduction in the odds of suicide compared to placebo/no lithium (OR = .27, p < .001; k = 12), but not compared to active controls (OR = .89, p = .468; k = 7). In psychotic disorders, clozapine was associated with a reduction in the odds of suicide (OR = .46, p = .007; k = 7). Associations between suicide death and electroconvulsive therapy (OR = .77, p = .053; k = 11), non-clozapine antipsychotics in bipolar disorder (OR = .73, p = .090; k = 6) and antipsychotics in psychotic disorders (OR = .39, p = .069; k = 6) were not significant. There was no consistent relationship between antiepileptic mood stabilizers and suicide. There were insufficient studies to meta-analyze associations of suicide risk with vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, or transcranial direct current stimulation.

Conclusion: Lithium and clozapine have consistent data supporting protective effects against suicide in certain clinical contexts.Reprinted from Depress Anxiety 2022; 39:100-112, with permission from John Wiley and Sons. Copyright © 2022.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药物治疗和躯体治疗对成人自杀的影响:系统回顾与元分析》。
背景:自杀是一场公共卫生危机。我们对精神药物疗法和躯体疗法对自杀风险的影响进行了系统回顾和荟萃分析:方法:我们对 MEDLINE 进行了系统检索,以了解评估药物(不包括抗抑郁药)或躯体干预对自杀风险影响的研究。如果研究中使用了对比组、报告了自杀死亡案例、评估了精神药理学或躯体疗法的干预效果,且研究对象为成年人,则将其纳入研究范围。研究质量采用纽卡斯尔-渥太华量表进行评估。从2940条审阅过的引文中纳入了57项研究:结果:在双相情感障碍患者中,与活性对照组相比,锂能降低自杀几率(几率比[OR] = .58,p = .005;k = 12),与安慰剂/无锂相比,也能降低自杀几率(OR = .46,p = .009;k = 9)。在混合诊断样本中,与安慰剂/不使用锂相比,锂可降低自杀几率(OR = .27,p < .001;k = 12),但与活性对照组相比则没有降低自杀几率(OR = .89,p = .468;k = 7)。在精神障碍患者中,氯氮平可降低自杀几率(OR = .46,p = .007;k = 7)。自杀死亡与电休克疗法(OR = .77,p = .053;k = 11)、双相情感障碍非氯氮平类抗精神病药物(OR = .73,p = .090;k = 6)和精神病性障碍抗精神病药物(OR = .39,p = .069;k = 6)之间的关系并不显著。抗癫痫情绪稳定剂与自杀之间没有一致的关系。没有足够的研究对迷走神经刺激、经颅磁刺激、癫痫磁疗或经颅直流电刺激与自杀风险的关系进行元分析:锂和氯氮平具有一致的数据支持在某些临床情况下对自杀具有保护作用。Copyright © 2022.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Call to Action for Starting Clozapine: Increasing Clozapine Use and Safety in a Post-REMS Era. From Theory to Therapy: The Evolution and Future of Cognitive-Behavioral Therapy for Psychosis in U.S. Mental Health Care. Why Not Rock the Boat? Deprescribing Anticholinergic Medications That Are No Longer Needed in Persons With Schizophrenia. Do We Now Have the Tools to Meaningfully Improve Outcomes for People With Schizophrenia? Xanomeline-Trospium for the Treatment of Schizophrenia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1